Altimmune to announce 12-week data from alt-801 phase 1 trial on september 28, 2021

Gaithersburg, md., sept. 27, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week phase 1 clinical trial of alt-801 in overweight and obese subjects in a pre-market press release and webcast to be held on tuesday, september 28, 2021.
ALT Ratings Summary
ALT Quant Ranking